Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS StudySerena Ruggieri, Claudio Gasperini, Alvino Bisecco et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 18
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Daniela Cargnelutti, Federica Matrone et al.|Journal of Neurology|2023Cited by 12